Exercise Fights Brain Aging Through a Hidden Liver-Brain Signal
Aerobic exercise triggers the liver to release FGF21, which clears damaged mitochondria from brain immune cells, reducing neuroinflammation and restoring memory in aged mice.
Summary
Scientists have uncovered a molecular chain reaction explaining how exercise protects the aging brain. In aged mice, 16 weeks of treadmill running boosted production of a liver hormone called FGF21. This hormone travels to the brain, where it activates a cellular cleanup process in microglia — the brain's immune cells — called mitophagy, which removes damaged mitochondria. Without functional mitophagy, toxic mitochondrial DNA accumulates inside cells, triggering a chronic inflammatory cascade known as cGAS-STING signaling. By restoring mitophagy through the AMPK-TFEB pathway, FGF21 suppresses this inflammation and reverses cognitive decline. The findings identify FGF21 as a druggable target for age-related cognitive decline, offering a potential pharmacological alternative for people unable to exercise.
Detailed Summary
Cognitive decline and neuroinflammation are closely intertwined features of brain aging, yet the biological bridge between physical activity and neuroprotection has remained poorly understood. This study provides a detailed mechanistic account of how exercise benefits the aging brain through a peripheral-to-central signaling axis.
Researchers subjected aged male C57BL/6J mice to 16 weeks of treadmill exercise and observed improvements in cognitive function alongside reduced hippocampal neuroinflammation. Using bioinformatic analysis, they identified fibroblast growth factor 21 (FGF21) — a hormone secreted by the liver — as strongly induced by exercise but suppressed by aging itself.
To confirm FGF21's causal role, the team knocked down hepatic FGF21 expression genetically. This single manipulation was sufficient to abolish the cognitive and anti-inflammatory benefits of exercise. Pharmacological blockade of mitophagy — the selective degradation of damaged mitochondria — produced identical results, pointing to mitophagy as the critical downstream effector. Mechanistically, FGF21 activated the AMPK–TFEB axis in microglia, restoring lysosomal function and enabling efficient removal of dysfunctional mitochondria. When mitophagy was restored, cytosolic mitochondrial DNA (mtDNA) accumulation fell sharply, dampening cGAS-STING-driven inflammatory signaling in the hippocampus.
The implications are significant. The liver-brain axis described here positions the liver as an active participant in brain health during aging. FGF21 emerges as a translatable therapeutic target: recombinant FGF21 analogs already exist in clinical development for metabolic disease and could be repurposed for neuroinflammatory conditions.
Key caveats apply. The study was conducted entirely in male mice, limiting generalizability to women and to humans broadly. Full-text details on FGF21 dosing, exercise protocols, and mechanistic specifics are unavailable as this summary is based on the abstract only. Human validation remains essential before clinical translation.
Key Findings
- 16 weeks of aerobic exercise improved cognition and reduced hippocampal neuroinflammation in aged male mice.
- The liver hormone FGF21, induced by exercise but suppressed by aging, is required for these neuroprotective effects.
- FGF21 activates the AMPK-TFEB pathway in microglia, restoring mitophagy and lysosomal function.
- Restored mitophagy reduces cytosolic mtDNA buildup and suppresses cGAS-STING neuroinflammatory signaling.
- FGF21 is identified as a druggable liver-brain axis target for age-related cognitive decline.
Methodology
Aged male C57BL/6J mice underwent 16 weeks of treadmill exercise. FGF21's role was validated via hepatic knockdown and pharmacological mitophagy blockade. Bioinformatic analysis was used to identify FGF21 as an exercise-induced, aging-suppressed hepatokine.
Study Limitations
The study used only aged male mice, so findings may not directly translate to women or to humans. Summary is based on the abstract only, limiting assessment of full methodology, statistical rigor, and effect sizes. Human studies are needed to validate the liver-brain FGF21 axis in age-related cognitive decline.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: